IDEAYA Biosciences, Inc.’s IDYA share price has surged by 10.70%, which has investors questioning if this is right time to sell.

April 03, 2025--(BUSINESS WIRE)--Harmony Biosciences ... s innovative products business. Earlier, he worked at Deloitte Consulting in the strategy and operations practice, and at Merck & Co ...

Harmony Biosciences Holdings ... Pfizer’s innovative products business. Earlier, he worked at Deloitte Consulting in the strategy and operations practice, and at Merck & Co. in the company ...

MSD’s monoclonal antibody, indicated for 15 types of cancer, smashed industry records with sales of $27.3 billion in 2024, ...

Harmony Biosciences Holdings, Inc. today announced the appointment of Ron Philip to the Company's Board of Directors. Ron Philip is the President and Chief Executive Officer of Orbital Therapeutics.

Merck (NYSE: MRK), known as MSD outside of the United States ... global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges ...

The consumables segment accounted for the largest share by product & service segment in the biomarkers market in 2023. By product & service, the biomarkers market is categorized into consumables, ...

Learn more about whether Moderna, Inc. or Vericel Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The Pistoia Alliance, a global, not-for-profit alliance that advocates for greater collaboration in life sciences R&D, has released new findings on data-driven innovation and AI in life sciences in ...